A trial has been conducted of recombinant α2-interferon (reaferon) used in 32 patients with Ph'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.
|Number of pages||5|
|Publication status||Published - 1993|
Field of Science
- 3.2 Clinical medicine
- 1.1. Scientific article indexed in Web of Science and/or Scopus database